Shifting Medicine Forward

Drawing on a deep understanding of the underlying causes, Ichnos Sciences is pursuing truly disease-centric therapies in oncology and autoimmune conditions. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.

Our path toward disease-centric therapies

Oncology Pipeline
Candidate Target Preclinical Phase 1 Phase 2 Phase 3 Status
ISB 1342 CD38 x CD3 BEAT® 1.0
bispecific antibody
Relapsed/Refractory Multiple Myeloma
      Phase 1 Enrolling
ISB 1442 CD38 x CD47 BEAT® 2.0 bispecific antibody
Relapsed/Refractory Multiple Myeloma
      IND-Enabling Studies
ISB 2001 TREAT™ trispecific antibody
Hematologic Malignancies
      Discovery
ISB 2004 BEAT® 2.0 bispecific antibody
Hematologic Malignancies/ Solid Tumors
      Discovery
ISB 2005 TREAT™ trispecific antibody
Hematologic Malignancies
      Discovery
oncology pipeline
Compound:
ISB 1342
Target:
CD38 x CD3 BEAT® 1.0
bispecific antibody
Indication:
Relapsed/Refractory Multiple Myeloma
Phase:
phase-1
Status:
Phase 1 Enrolling
Compound:
ISB 1442
Target:
CD38 x CD47 BEAT® 2.0 bispecific antibody
Indication:
Relapsed/Refractory Multiple Myeloma
Phase:
preclinical
Status:
IND-Enabling Studies
Compound:
ISB 2001
Target:
TREAT™ trispecific antibody
Indication:
Hematologic Malignancies
Phase:
preclinical
Status:
Discovery
Compound:
ISB 2004
Target:
BEAT® 2.0 bispecific antibody
Indication:
Hematologic Malignancies/ Solid Tumors
Phase:
preclinical
Status:
Discovery
Compound:
ISB 2005
Target:
TREAT™ trispecific antibody
Indication:
Hematologic Malignancies
Phase:
preclinical
Status:
Discovery


BEAT®: Bispecific Engagement by Antibodies based on the T-cell receptor
TREAT™: Trispecific Engagement by Antibodies based on the T-cell receptor

 
Autoimmune Disease

Ichnos is out-licensing its autoimmune disease assets to enable greater focus on oncology. Explore the pipeline chart below to learn more and contact us at Corporate.Communications@ichnossciences.com for additional information.

Candidate Target Preclinical Phase 1 Phase 2 Phase 3 Status
ISB 830 (telazorlimab) (Licensing discussions ongoing) OX40 antagonist monoclonal antibody
Atopic Dermatitis (AD)*
      Phase 2b completed†
ISB 880 (Licensed to Almirall S.A) IL-1RAP antagonist monoclonal antibody
Autoimmune Disease
      IND-Enabling Studies Completed
autoimmune-disease
Compound:
ISB 830 (telazorlimab) (Licensing discussions ongoing)
Target:
OX40 antagonist monoclonal antibody
Indication:
Atopic Dermatitis (AD)*
Phase:
phase-2
Status:
Phase 2b completed†
Compound:
ISB 880 (Licensed to Almirall S.A)
Target:
IL-1RAP antagonist monoclonal antibody
Indication:
Autoimmune Disease
Phase:
preclinical
Status:
IND-Enabling Studies Completed

*A US IND for rheumatoid arthritis and other autoimmune indications is active.

†Primary efficacy endpoint (EASI score, % change, baseline to week 16) met at two highest doses tested. Numerical improvements were seen for the two higher-dose arms (300 mg and 600 mg q 2 weeks) of telazorlimab compared to placebo in the secondary endpoints of EASI-75 and Investigator Global Assessment, but the differences were generally not statistically significantly different from placebo.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

View Career Opportunities

All Locations

The links above are provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.